NEW YORK (GenomeWeb News) — Molecular diagnostics developer AdvanDx will use a $15 million blast of Series C financing from BioMérieux and two existing investors to push sales and marketing efforts and to expand its R&D facilities, the company said yesterday.
Joining BioMérieux in the financing is LD Pensions and Scandinavian Life Science Venture.
AdvanDx makes a suite of diagnostics for detecting, identifying, and managing pathogens and infections, including the PNA FISH and Evigene tests, which detect antibiotic-resistant bacteria.
BioMérieux in May become Advent’s US distributor of tests for identifying Staphylococcus aureus, Candida albicans, and Enterococcus faecalis.